BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period
RA Capital Management closed the venture capital firm’s second venture fund at $461 million, aimed at a continued investment strategy into privately held life sciences companies.
Boston-based venture capital firm Vida Ventures raised $600 million for the new, oversubscribed life science fund Vida Ventures II.
Third Rock Ventures closed on a new fund, the largest in the Boston-based venture capital firm’s 12-year history.
For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.
Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in […]
